Batte brewing over the BRCA 1/2 gene patents
Rev. derecho genoma hum
; (33): 171-194, jul.-dic. 2010.
Artigo
em Inglês
| IBECS
| ID: ibc-92127
Biblioteca responsável:
ES1.1
Localização: BNCS
RESUMEN
El revolucionario descubrimiento del AND y la descripción completa del genoma humano han permitido a los científicos de todo el mundo participar en una investigación sin precedentes a la vanguardia de la tecnología biomédica, como es la ingeniería genética (manipulación genética o ADN recombinante). Sin embargo, como suele ocurrir con las modernas biotecnologías, la innovación relacionada con los genes depende, en gran medida, de la fuerte protección de las patentes principalmente debido al alto coste de la investigación y comercialización en esta área. El objetivo de este trabajo es proporcionar una descripción de la Sentencia del Tribunal de Distrito en el caso de la Asociación de Patología Molecular y oros contra la Oficina de Patentes y Marcas de los EE.UU y otros (Unión Americana de Libertades Civiles, ABSTRACT
The revolutionary discovery of the DNA and the successful mapping of the human genome have allowed scientists worldwide to engage in an unprecedented research on the cutting-edge biomedical technology such as the genetic engineering (gene-splicing or recombinant DNA). However, as is often the case with modern bio-technologies, genes related innovation is heavity dependent on strong patent protection primarily due to high costs of research and commercialization in this area. The aim of this paper is to provide a description o the District Court Ruling in the case of Association for Molecular Pathology et al v United States Patent and Trademark Office et al (ACLU y Myriad). In doing so, the article provides information on the relevant background at issues, including a brief introduction to general patentability requirements in relation to genes and the controversy surrounding the patentability of genetic material. The analysis of the complaint filed in the ACLU y Myriad case and the details of the District Court Ruling follows. The paper concludes with an outlook of the future legal actions involving Myriad´s BRCA 1/2 and the assessment of the potential impact that the BRCA 1&2 District Court Ruling and subsequent appeal(s) may have on the American patent law (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Engenharia Genética
/
Genes BRCA1
/
Predisposição Genética para Doença
/
Genes BRCA2
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. derecho genoma hum
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
Helsinki University/Finland